Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
The Current Therapeutic Landscape in Unresectable Stage III NSCLC
Stephen Liu, MD
Joshua K. Sabari, MD
Susan Scott, MD
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)
Applications of Emerging Data in Resectable NSCLC
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Scott Kopetz, MD, PhD
Cathy Eng, MD, FACP
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS
Komal Jhaveri, MD, FACP
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.